Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of CT-L01 vs. Alogliptin and Metformin XR in Healthy Volunteers
NCT05363592Phase 1Completed
- Sponsor
- Celltrion
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alogliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Celltrion. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration and Peak Plasma Concentration. Started Jun 2022; status: completed.
02
Drugs
alogliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05363592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363592.